NASDAQ:IMCR Immunocore (IMCR) Stock Price, News & Analysis $27.76 -0.79 (-2.77%) As of 11:46 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Immunocore Stock (NASDAQ:IMCR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Immunocore alerts:Sign Up Key Stats Today's Range$27.79▼$29.2550-Day Range$24.53▼$30.6352-Week Range$23.15▼$58.36Volume93,191 shsAverage Volume427,862 shsMarket Capitalization$1.39 billionP/E RatioN/ADividend YieldN/APrice Target$58.13Consensus RatingModerate Buy Company OverviewImmunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.Read More… Immunocore Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreIMCR MarketRank™: Immunocore scored higher than 60% of companies evaluated by MarketBeat, and ranked 425th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingImmunocore has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 6 buy ratings, 3 hold ratings, and 1 sell rating.Amount of Analyst CoverageImmunocore has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Immunocore's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Immunocore are expected to decrease in the coming year, from ($0.94) to ($1.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immunocore is -30.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immunocore is -30.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunocore has a P/B Ratio of 3.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted16.29% of the float of Immunocore has been sold short.Short Interest Ratio / Days to CoverImmunocore has a short interest ratio ("days to cover") of 25.3, which indicates bearish sentiment.Change versus previous monthShort interest in Immunocore has recently increased by 3.52%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImmunocore does not currently pay a dividend.Dividend GrowthImmunocore does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted16.29% of the float of Immunocore has been sold short.Short Interest Ratio / Days to CoverImmunocore has a short interest ratio ("days to cover") of 25.3, which indicates bearish sentiment.Change versus previous monthShort interest in Immunocore has recently increased by 3.52%, indicating that investor sentiment is decreasing. News and Social Media3.5 / 5News Sentiment1.28 News SentimentImmunocore has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.82 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Immunocore this week, compared to 5 articles on an average week.Search Interest1 people have searched for IMCR on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Immunocore to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Immunocore insiders have bought more of their company's stock than they have sold. Specifically, they have bought $23,994,085.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders10.40% of the stock of Immunocore is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions84.50% of the stock of Immunocore is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Immunocore's insider trading history. Receive IMCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunocore and its competitors with MarketBeat's FREE daily newsletter. Email Address IMCR Stock News HeadlinesQ2 EPS Estimates for Immunocore Lifted by Leerink PartnrsMay 13 at 2:18 AM | americanbankingnews.comCantor Fitzgerald Forecasts Stronger Earnings for ImmunocoreMay 12 at 3:15 AM | americanbankingnews.comThe Silver Squeeze Is Already Here—Are You Ready?A Silver Supply Crunch + Rising Demand = A Perfect Storm. Here's What You Need To KnowMay 14, 2025 | Priority Gold (Ad)Immunocore stock rises as Q1 results top estimatesMay 7, 2025 | investing.comImmunocore reports first quarter financial results and provides a business updateMay 7, 2025 | globenewswire.comImmunocore Holdings: A Name On My Watch ListApril 27, 2025 | seekingalpha.comJ.P. Morgan Remains a Buy on Immunocore Holdings (IMCR)April 15, 2025 | markets.businessinsider.comImmunocore Holdings (IMCR) Gets a Buy from NeedhamApril 10, 2025 | markets.businessinsider.comSee More Headlines IMCR Stock Analysis - Frequently Asked Questions How have IMCR shares performed this year? Immunocore's stock was trading at $29.50 at the beginning of 2025. Since then, IMCR stock has decreased by 3.2% and is now trading at $28.55. View the best growth stocks for 2025 here. How were Immunocore's earnings last quarter? Immunocore Holdings plc (NASDAQ:IMCR) issued its earnings results on Wednesday, May, 7th. The company reported $0.10 earnings per share for the quarter, beating analysts' consensus estimates of ($0.35) by $0.45. The company's revenue for the quarter was up 33.6% on a year-over-year basis. When did Immunocore IPO? Immunocore (IMCR) raised $199 million in an initial public offering on Friday, February 5th 2021. The company issued 8,300,000 shares at a price of $23.00-$25.00 per share. Goldman Sachs, J.P. Morgan and Jefferies served as the underwriters for the IPO. Who are Immunocore's major shareholders? Immunocore's top institutional shareholders include Primecap Management Co. CA (5.35%), Fiera Capital Corp (1.61%), Principal Financial Group Inc. (0.96%) and Massachusetts Financial Services Co. MA (0.92%). Insiders that own company stock include Bros Advisors Lp Baker and Leger Tina Amber St. View institutional ownership trends. How do I buy shares of Immunocore? Shares of IMCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Immunocore own? Based on aggregate information from My MarketBeat watchlists, some other companies that Immunocore investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET) and e.l.f. Beauty (ELF). Company Calendar Last Earnings5/07/2025Today5/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IMCR CIK1671927 Webwww.immunocore.com Phone44-12-3543-8600FaxN/AEmployees320Year FoundedN/APrice Target and Rating Average Stock Price Target$58.13 High Stock Price Target$100.00 Low Stock Price Target$24.00 Potential Upside/Downside+109.4%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($0.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-55,290,000.00 Net Margins-15.87% Pretax Margin-18.14% Return on Equity-12.84% Return on Assets-5.09% Debt Debt-to-Equity Ratio1.03 Current Ratio3.78 Quick Ratio3.76 Sales & Book Value Annual Sales$310.20 million Price / Sales4.48 Cash FlowN/A Price / Cash FlowN/A Book Value$7.42 per share Price / Book3.74Miscellaneous Outstanding Shares50,068,000Free Float45,480,000Market Cap$1.39 billion OptionableOptionable Beta0.75 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free Report This page (NASDAQ:IMCR) was last updated on 5/14/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredSilver’s 332% Surge?Silver has quietly become one of the most promising investments of this cycle. Russia is now stockpiling silve...Lear Capital | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump Quietly Planning $15 Trillion Crypto ShockerMost investors are still unaware, but I believe a new White House action may have quietly opened the floodgate...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunocore Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunocore With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.